Compared with traditional antibodies, nanobodies, considered next-generation antibody-derived tools, were developed and evaluated in different stages of clinical trials for cancer treatment.517 GB18-06, a nanobody specifically directed against GDF15, effectively blocks the GDF15-GFRAL signaling pathway in vitro and reduces weight loss (>20%) in HT1080 tumor-bearing mice.518 Bringing these drugs into clinical research as soon as possible will greatly benefit patients with cachexia. This evidence concerns the gene GDF15 and Cachexia.